RHOTRIMINE CAPSULE

Страна: Канада

Език: английски

Източник: Health Canada

Купи го сега

Активна съставка:

TRIMIPRAMINE (TRIMIPRAMINE MALEATE)

Предлага се от:

SANOFI-AVENTIS CANADA INC

АТС код:

N06AA06

INN (Международно Name):

TRIMIPRAMINE

дозиране:

75MG

Лекарствена форма:

CAPSULE

Композиция:

TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 75MG

Начин на приложение:

ORAL

Броя в опаковка:

100

Вид предписание :

Prescription

Терапевтична област:

TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS

Каталог на резюме:

Active ingredient group (AIG) number: 0102479005; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2007-03-29

Данни за продукта

                                PRODUCT MONOGRAPH
RHOTRIMINE
®
(Trimipramine)
12.5, 25, 50 and 100 mg Tablets
75 mg Capsules
Tricyclic Antidepressant
sanofi-aventis Canada Inc.
Date of Preparation:
2150 St. Elzear Blvd. West
May 19, 2006
Laval, Quebec H7L 4A8
Control No. 105835
s-a Version 1.0 dated
2
ACTION
RHOTRIMINE (trimipramine) is a tricyclic antidepressant with sedative
properties. It has also
anticholinergic properties and potentiates the sympathetic responses,
presumably by blocking the
re-uptake of norepinephrine which has been released by the presynaptic
neurones. Trimipramine has
a quinidine-like effect on the heart and produces E.K.G and E.E.G.
changes similar to those of other
tricyclic antidepressants.
INDICATIONS
RHOTRIMINE (trimipramine) is indicated in the drug treatment of
depressive illness. It is
particularly effective in endogenous depression. It may also be useful
in some patients with neurotic
depression.
CONTRAINDICATIONS
RHOTRIMINE (trimipramine) is contraindicated in cases of known
hypersensitivity to the drug. The
possibility of cross-sensitivity with other dibenzazepine compounds
should also be kept in mind.
Monoamine oxidase inhibitors should not be administered concomitantly
with RHOTRIMINE and
a two-week delay is recommended before using the drug in patients who
have received an MAO
inhibitor. Treatment with RHOTRIMINE should be started with small
doses and increased
progressively, depending on tolerance and response.
Because of its anticholinergic properties, RHOTRIMINE is
contraindicated in patients with narrow
angle glaucoma and prostatic hypertrophy.
It is also contraindicated during the acute recovery phase following
myocardial infarction and in the
presence of acute congestive heart failure.
WARNINGS
Tricyclic antidepressants, particularly in high doses, have been
reported to produce arrhythmias,
sinus tachycardia, and prolongation of conduction time. A few
instances of unexpected death have
been reported in patients with cardiovascular disorders. Myocardial
infarction and stroke have also
been reported wi
                                
                                Прочетете целия документ
                                
                            

Документи на други езици

Данни за продукта Данни за продукта френски 20-12-2007

Сигнали за търсене, свързани с този продукт

Преглед на историята на документите